Cargando…

Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses

BACKGROUND: Immunomodulatory/immunosuppressive activity of multiple sclerosis (MS) disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 exposure or vaccination in patients with MS (PwMS). We evaluated the effect of DMTs on humoral and cell-mediated immune responses to 2 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milo, Ron, Staun-Ram, Elsebeth, Karussis, Dimitrios, Karni, Arnon, Hellmann, Mark A., Bar-Haim, Erez, Miller, Ariel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012137/ https://www.ncbi.nlm.nih.gov/pubmed/35432335 http://dx.doi.org/10.3389/fimmu.2022.868915

Ejemplares similares

Multiple Sclerosis-Associated Gut Microbiome in the Israeli Diverse Populations: Associations with Ethnicity, Gender, Disability Status, Vitamin D Levels, and Mediterranean Diet
por: Nitzan, Zehavit, et al.
Publicado: (2023)

A case report of unilateral cervical lymphadenopathy and multiple cranial neuropathies following mRNA-COVID-19 vaccination
por: Shalabi, Fatma, et al.
Publicado: (2022)

Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells
por: Staun-Ram, Elsebeth, et al.
Publicado: (2018)

Multiple Sclerosis
por: Karussis, Dimitrios
Publicado: (2017)

Human trophoblast function during the implantation process
por: Staun-Ram, Elsebeth, et al.
Publicado: (2005)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
por: Yahav, Dafna, et al.
Publicado: (2021)

COVID-19 vaccine hesitancy among Israeli adults before and after vaccines’ availability: A cross-sectional national survey
por: Frankenthal, Dvora, et al.
Publicado: (2022)

Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion
por: Staun-Ram, Elsebeth, et al.
Publicado: (2009)

Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
por: Wang, Meng, et al.
Publicado: (2023)

Interferon-Beta Induces Distinct Gene Expression Response Patterns in Human Monocytes versus T cells
por: Henig, Noa, et al.
Publicado: (2013)

Correction for Israeli et al., “Draft Genome Sequence of a Rare Israeli Clinical Isolate of Burkholderia pseudomallei”
por: Israeli, Ofir, et al.
Publicado: (2019)

Vaccine injury compensation: the Israeli case
por: Kamin-Friedman, Shelly, et al.
Publicado: (2021)

Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
por: Petrou, Panayiota, et al.
Publicado: (2022)

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
por: Ali, Ahya, et al.
Publicado: (2021)

Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion
por: Staun-Ram, Elsebeth, et al.
Publicado: (2004)

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
por: Apostolidis, Sokratis A., et al.
Publicado: (2021)

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination
por: Israel, Ariel, et al.
Publicado: (2022)

Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties
por: Golan, Daniel, et al.
Publicado: (2013)

Growth, developmental achievements and vaccines timeliness of undocumented migrant children from Eritrea compared with Israelis
por: Mor, Zohar, et al.
Publicado: (2018)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

Vaccine hesitancy as self-determination: an Israeli perspective
por: Velan, Baruch
Publicado: (2016)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
por: Meyer-Arndt, Lil, et al.
Publicado: (2022)

Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
por: Itchaki, Gilad, et al.
Publicado: (2021)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
por: López-Cortés, Luis F., et al.
Publicado: (2023)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
por: Tütüncü, Melih, et al.
Publicado: (2023)

T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial
por: Karussis, Dimitrios, et al.
Publicado: (2012)

The Association of Previous Vaccination with Live-Attenuated Varicella Zoster Vaccine and COVID-19 Positivity: An Israeli Population-Based Study
por: Merzon, Eugene, et al.
Publicado: (2022)

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
por: Mairhofer, Mario, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
por: Lyski, Zoe L., et al.
Publicado: (2022)

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
por: Oyaert, Matthijs, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients
por: Kwiatkowska, Ewa, et al.
Publicado: (2022)

Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
por: Filippini, Federica, et al.
Publicado: (2023)

Prediction of vaccine hesitancy based on social media traffic among Israeli parents using machine learning strategies
por: Bar-Lev, Shirly, et al.
Publicado: (2021)

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
por: Ciampi, Ethel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n39kuo859km790t0i83ila2ssk